By Malvika Gurung
Investing.com — The pharmaceutical firm Glenmark Prescription drugs (NS:) reported its earnings for the March-ending quarter on Saturday, recording a fall in its revenue determine within the interval.
Its consolidated revenue after tax declined 26% on a YoY foundation to Rs 173 crore in This fall FY22, in comparison with Rs 234 crore reported within the year-ago interval.
Glenmark’s board of administrators have beneficial a dividend of Rs 2.5/share for FY22.
The corporate’s consolidated revenues climbed 6% YoY to Rs 3,019 crore within the quarter below assessment, and 12.4% YoY to Rs 12,305 crore within the full monetary yr 2021-22. Within the yr, its PAT marginally rose by 2.5% YoY to Rs 994 crore.
The agency efficiently listed its subsidiary Glenmark Life Sciences (NS:) within the Indian exchanges, out-licensed the deal for ISB 880 with Almirall and gained approval for the Ryaltris from the USFDA to determine the drug firm because the main innovation-driven pharma firm in India, acknowledged the corporate’s Chairman and MD Glenn Saldanha, as cited by PTI.
He added, “We delivered constant efficiency all year long and achieved our key targets, regardless of the difficult international macro surroundings.”